FDA approval
September 27, 2010
THE US Food and Drug
Administration has approved a new
combined oestrogen/progestin oral
contraceptive pill, Beyaz, which also
contains folate (levomefolate
calcium 0.451 mg).
The manufacturer added folate
for the purpose of reducing the risk
of neural tube defect in a pregnancy
conceived whilst taking Beyaz, or
shortly after its discontinuation.
Beyaz is based on YAZ and
contains the same levels of
estrogen and progestin, and is
approved for the prevention of
pregnancy, the treatment of
premenstrual dysphoric disorder
(for women who choose an oral
contraceptive), the treatment of
moderate acne vulgaris in women
at least 14 years of age and who
chose an oral contraceptive for
birth control, and to raise folate
levels in women on the pill.
MEANWHILE the FDA has also
published a complete list of
products recalled as part of the
Abbott instant formula recall in
Sep, see www.fda.gov.au.
The above article was sent to subscribers in Pharmacy Daily's issue from 27 Sep 10To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 27 Sep 10
